Type: Oral
Session: 506. Bone Marrow Microenvironment: The Bone Marrow Microenvironment in Disease
Hematology Disease Topics & Pathways:
Research, Fundamental Science, MDS, Translational Research, CHIP, Chronic Myeloid Malignancies, Hematopoiesis, Diseases, Myeloid Malignancies, Biological Processes
To investigate how extrinsic inflammatory cues from non-hematopoietic stromal cells contribute to disease progression, we transplanted Tet2-/- HSPCs into lethally-irradiated Gsdmd whole-body knockout (Gsdmd-/-) mice and their WT littermates (five-month-old donors to five-month-old recipients). In this model, Gsdmd-/- mice provides a Gsdmd-null bone marrow microenvironment. Eight months post-transplantation, we found that, unlike their WT counterparts, Gsdmd-/- mice failed to develop CH to MDS transformation upon receiving Tet2-/- HSPCs. The histological features of the bone marrow and spleen were significantly retained in Gsdmd-/- recipients. We observed that loss of Gsdmd in the bone marrow microenvironment significantly reverted anemia and monocytosis. In addition, we conducted single-cell RNA-seq (scRNA-seq) on bone marrow mononuclear cells from these mice. Our findings revealed a notable increase in inflammatory macrophages and exhausted T cells within the ‘Tet2-/- to WT’ group. Remarkably, this phenotype was significantly mitigated in the Gsdmd-/- recipients. These data collectively indicate that Gsdmd in the non-hematopoietic bone marrow microenvironment plays a critical role in the progression of CH in this model.
Xenium Spatial Transcriptomic Analyses provided further insights into the cellular architecture and interactions within the bone marrow environment. Being consistent with our scRNA-seq data, we observed a marked increase of inflammatory macrophages in ‘Tet2-/- to WT’ group. Notably, the Xenium analysis revealed a distinct cell-cell interaction between inflammatory macrophages and non-hematopoietic stromal cells. This interaction was exclusively observed in ‘Tet2-/- to WT’ group, whereas it was abolished in the ‘Tet2-/- to Gsdmd-/-’ group, suggesting a specific mechanistic pathway through which Gsdmd protein in non-hematopoietic stromal cells may facilitate the communication between inflammatory macrophages and stromal cells. This finding implies that Tet2 mutation in hematopoietic cells alone is insufficient to drive this interaction; rather, it is the presence of Gsdmd in the non-hematopoietic stromal cells that appears to be the key in mediating this communication, highlighting a novel dimension of the inflammatory response regulated by the bone marrow microenvironment.
Additionally, we have developed GSDMD knockout iPSCs to construct GSDMD-null human bone marrow organoids. GSDMD knockout did not affect the formation and composition of the bone marrow organoids. Preliminary data indicate that CD34+ cells from MDS patients with a TET2 loss-of-function mutation exhibit significantly increased myeloid differentiation when engrafted into WT organoids. Conversely, this myeloid-skewed differentiation is notably reduced in GSDMD-null organoids. These data highlight the important role of GSDMD in bone marrow microenvironment in human context.
By employing both murine models and human bone marrow organoids, we demonstrated that the absence of GSDMD in the bone marrow stromal cells significantly impedes the development of CH and its associated inflammatory responses.
Disclosures: Ji: Baim Institute for Clinical Research: Consultancy; Aplexis, Inc.: Current equity holder in private company, Patents & Royalties, Research Funding.
See more of: Oral and Poster Abstracts